Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JACDS Council Holds Hearings on Remote Sales of OTC Drugs
December 2, 2011
- Original Drug Makers Should Let Go of Long-Listed Drugs
December 1, 2011
- Early Exploratory Studies Should Be Conducted in Japan for Japan-originated New Drugs: FPMAJ Chairman Shoda
December 1, 2011
- HGPI Holds Forum on Global Measures for NCD Issues
November 30, 2011
- Japanese Respiratory Foundation to Promote Research, Awareness of Respiratory Diseases
November 30, 2011
- Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
- MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
- SAMURAI Biotech Association Presents Petition to Health Minister Calling for NHI Pricing System Reflecting Economic Assessment
November 25, 2011
- JPMA, FPMAJ Call on LDP Council on Budget and Tax System with Requests for Next Year
November 24, 2011
- JACDS Discusses Problems Expected from Ban on Dispensing Point Services
November 21, 2011
- Plaintiffs Appeal to the Supreme Court: Iressa Appeal Trial
November 18, 2011
- 6 Indian Generics Companies Including Zydus Form Association, to Start Operations This Month
November 18, 2011
- JPMA Postpones Announcement of Views on TPP,“Will Not Comment Based on Speculation”
November 17, 2011
- Plaintiffs Say High Court Ruling over Iressa “Completely Denies Goals in Medical Administration”
November 17, 2011
- Top JPWA Officials Stress Importance of Wholesalers in Urgent Press Conference
November 17, 2011
- NEDO Decides to Provide Assistance to Four Projects to Develop Bio-Pharmaceutical Manufacturing Technology
November 16, 2011
- JPMA Campaign Highlights Value of New Drug Development
November 15, 2011
- Foreign Countries Interested in Japan’s New Promotion of Generics: IGPA Annual Conference
November 14, 2011
- Premium for Development of New Drugs Is Fiscal Neutrality System: Mr Kamoya of JPMA
November 11, 2011
- JPWA's Bessho Says Promotion of Unit-Priced Contracts by Product First and Foremost
November 11, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…